Acute Colorectal and Anoproctology Flashcards
(111 cards)
Define “Massive Lower Gastrointestinal Bleeding”
What proportion of massive LGIB is actually UGI in aetiology?
Massive LGIB is defined as bleeding distal to the ligament of Treitz associated with haemodynamic abnormality.
Between 15-20% of massive LGIBs are UGIBs.
This has lead to a recent proposal to reserve the term LGIB for bleeding occuring distal to the ICV.
What is the mortality rate associated with LGIB?
What factors affect this?
A recent UK audit showed a 3-4% mortality associated with LGIB.
This was higher in inpatients who develop LGIB compared with outpatients who present with LBIG, which reflects the underlying comorbidities associated with inpatients who bleed.
Provide an overview of the causes of lower GI bleeding
LGIB is most common in elderly patients with multiple comorbidities; however, causes vary by age. In adolescents, common causes are Meckel’s diverticula, IBD, and benign polyps. LGIB in adults is most often caused by colonic diverticula, cancer, and angiodysplasia.
In a recent audit of UK data:
-
Diverticulosis 20-65%
- Self-limiting 80% of the time
- Often not a formal diagnosis (25% of audit diagnoses)
-
Colitis 15%
- Ischaemic
- Inflammatory bowel disease
- Infectious
-
Haemorrhoids 3-15%
- Rarely cause massive LGIB
-
Angiodysplastic lesions 3-15%
- Over-represented in massive LGIB 20-30%!
- Over two thirds are >70 years old
- More commonly in the right colon (54%)
-
Iatrogenic bleeding 5-10%
- Post-polypectomy; immediate and delayed
- Post-colorectal surgery
- Post radiotherapy
-
Malignancy
- Often occult, rarely massive LGIB
-
Miscellaneous:
- Varices, Rectal ulceration, Dieulafoy lesions, NSAIDS, Meckel’s
What are the key principles in managing LGIB?
Which index should be used in the assessment of potentially massive LGIB? What is its utility?
- Simultaneously assess and resuscitate
- Determine the severity of bleeding
- Determine the location of the bleeding
- Determine the cause of the bleeding.
The British guidelines advocate the use of the shock index (HR/SBP) with a value greater than 1 as an indicator of ongoing bleeding.
Increasing shock index is associated with increasing risk of mortality and it is widely used in the trauma literature.
A shock index >1 is also a predictor of detecting a contrast blush on CT angiography and therefore may be useful in identifying patients who would benefit from CTA and likely need therapeutic intervention.
Describe the key features of a focussed history when assessing a patient with lower GI bleeding.
- HPC:
- Timing, frequency, and volume of the bleeding
- Associated symptoms
- PMHx:
- Anticoagulant / anti-platelet use
- Previous colonoscopy
- History of bleeding diathesis
- History of IBD
- History of irradiation
- History of liver disease
What are the guidelines for NG placement in lower GI bleeding?
The American guidelines recommend placement of a nasogastric tube and lavage to assess for an UGIB source; however, the British guideline advise against this practice as it does not reliably aid diagnosis, affect outcomes and maybe associated with complications in up to a third of patients.
Reliance on a negative nasogastric tube aspirate to exclude an UGIB has poor sensitivity and low negative predictive value (64%).
Describe the principles of blood transfusion in lower GI bleeding.
Cite Hb thresholds and targets in your answer.
- All the guidelines recommend a restrictive approach to blood product transfusion with a threshold haemoglobin of 70g/L in haemodynamically stable patients with a target haemoglobin of 70-90 g/L.
- In patients with ischaemic heart disease or significant comorbidity this threshold can be increased to 80g/L with a target haemoglobin of 80-100g/L.
- Haemodynamically unstable patients should be actively resusciated with a massive transfusion protocol in consultation with a haemotologist to target a haemoglobin of 90g/L.
- There is no randomised data from patients with LGIB to support these recommendations. They are derived from UGIB data where a recent meta-analysis has demonstrated increased survival when a restrictive blood transfusion strategy is adopted.
- A separate systematic review has shown that a restrictive transfusion strategy in patients with ischaemic heart disease, previous stroke and vascular disease have an increased risk of myocardial infarction and death.
What is the evidence for TXA use in lower GI bleeding?
The HALT-IT trial, published in 2020, demonstrated that patients administered 4g TXA after acute GI bleeding experienced more venous thromboembolic events than controls (0.8% vs 0.4%, RR 2.11) without a concomitant reduction in death or rebleeding at 24hrs, 5 days, or 28 days.
Use of TXA is not recommended in the setting of acute LGIB.
How can patients with lower GI bleeding be risk-stratified?
-
The Oakland Score
- Recommended by British Guidelines
- Clinical and demographic data with various weighting
- Safe discharge with OP scope if score is less than 8
-
The NOBLADS score
- Developed in Japan, validated internationally
- 8 parameters, all easily assessed on admission
- Score ≥5 = ~80% severe bleeding risk (≥2URBC)
- Score <4 = ~2% severe bleeding risk
- Safe discharge and OP scope if score less than 2
-
The Strate score
- Derived from multivariate analysis
- Provides OR for severe bleeding
- Similar to NOBLADS parameters.
What proportion of patients presenting with lower GI bleeding are on anticoagulation?
30% are on either anti-platelets or anti-coagulants
5% are on dual antiplatelet therapy or antiplatelets + anti-coagulants.
In the setting of lower GI bleeding, how do you address:
Warfarin?
Dabigatran?
Rivaroxiban / Apixaban?
Aspirin?
DAPT?
Heparin?
- Warfarin
- Cease and reverse with PTX + FFP if INR >2.0
- Recommence 7 days later where feasible
- Bridge with Heparin in high risk patients
- Dabigatran
- Cease and reverse with Idarucizumab
- Rivaroxiban / Apixaban
- Cease and reverse with Adexanet alfa (both direct and indirect Factor Xa inhibitors)
- Aspirin
- Cease in primary prevention
- Continue in secondary prevention
- DAPT
- DAPT for cardiac stents should be discussed with cardio
- In massive LGIB, P2Y12 inhibitors (e.g Cloipidogrel) should be ceased while Aspirin continues
- Patients on DAPT have a 5-fold risk of re-bleeding
- Heparin
- Reverse with Protamine sulfate
- Ciraparantag is a small molecule drug which binds UFH and LMWH - not widely in use
For elective colonoscopy, when should Warfarin, DOACS, and antiplatelets be withheld from and when should they be resumed?
- Warfarin
- withhold from 5 days
- resume same day
- DOACS
- withhold from 2 days
- resume next day
- Aspirin
- do not stop
- P2Y12 agents
- withhold for 7 days
- resume within 24 hours
What is the role of colonoscopy in lower GI bleeding?
- Colonoscopy should be the first-line diagnostic investigation in haemodynamically stable patients to investigate a major LGIB.
- If the bleed is major (Oakland score >8) = inpatient
- If the bleed is minor (Oakland ≤8 points) = outpatient
- A major advantage of colonoscopy is that it can be used simultaneously to provide definitive therapy in up to 60% of cases
- Inpatient colonoscopy requires prep as caecal intubation rates are ~60% without prep. This adds complexity to the case and the risks of inpatient prep following bleeding should be balanced with the expediency of diagnosis.
What colonoscopic therapeutic modalities exist for control of lower GI bleeding?
- Clipping via through the scope clips
- Can be applied to post-polypectomy site
- Can be applied to the base of a bleeding divertic for tamponade
- Adrenaline injection
- 20% re-bleed rate if used as monotherapy!
- Endoscopic band ligation
- Technically more challenging but lower re-bleed rates cf clips
- Argon Plasma Coagulation
- Angioectatic lesions
- 20-60W, 1-2L flow, 1-2 sec pulses, 1-3mm from lesion
- Haemostatic powders
- Hemospray
- Caution with liberal use in heavy bleeding - embolises
Describe the role of interventional radiology in lower GI bleeding.
Overall success rates?
Strengths and weaknesses of the various approaches?
IR can be used to both localise and treat lower GI bleeding, with an overall success rate of 85% with regard to haemostasis.
In the haemodynamically unstable patient experiencing a massive LGIB, CTA is recommended before any therapy is instigated. CTA can detect bleeding as slow as 0.3ml/min. Expedited transfer to angioembolization is required, and some consider this to be a KPI in IR units.
Catheter angiography requires a faster rate of bleeding (1ml/min) for diagnostic purposes. Super selective angioembolization involves the embolization with absorbable gelatin sponges, cyanoacrylate glue, ethylene, or polyvinyl alcohol, and microcoils to control haemorrhage.
A systematic review reported that this technique can be successful in achieving immediate haemostasis in between 40-100% of cases with re-bleeding rates reported between 0-50%
Describe the risks of IR-angioembolization
- Contrast nephropathy
- Bleeding
- Pseudoaneurysm formation
- Thromboembolic events
- Colonic ischaemia
- Can occur if angioembolization is not super-selective.
- This can result in a spectrum of clinical presentation from self-limiting ischaemic colitis to perforation and associated peritonitis
Describe the management algorithm for lower GI bleeding put forward by the British Society of Gastroenterology

What is the cryptoglandular theory and why is it incomplete?
The cryptoglandular theory can be summarised in three steps;
- Cystic dilatation of an anal gland (obstructive or congenital)
- Infection of the anal gland leading to abscess formation
- Surgical or spontaneous drainage in the perianal skin leads to tract formation and epithelisation
Critical points against the cryptoglandular theory include;
- It is unlikely for an abscess to traverse intact skeletal muscle preferentially to an unimpeded path
- Most peri-anal abscesses do not result in fistula
- The theory doesn’t explain why fistula-in-ano is more common in males (12.3/100,000 versus 5.6/100,000)
- A scarcity of bowel derived bacteria in fistula tracts
Describe the pathophysiology of perianal fistulae in Crohn’s
- Based on the Epithelial to Mesenchymal Transition
- EMT is a normal physiological process in embryology and healing
- Indices of EMT include upregulated TGF-1, TGF-2, and β6-integrin with decreased expression of E-cadherin and β-catenin
- This pattern is observed in Crohn’s disease.
- EMT results in activation of matrix remodelling enzymes and induces expression of molecules involved with cellular invasion, creating a fistulating phenotype.
Is there a unifying theory of perianal fistula formation?
- The host’s innate immunity is unable to fully resolve an acute infection of an anal gland
- Persistence of bacterial remnants triggers EMT
- Activation of EMT leads to release of pro-inflammatory cytokines such as IL-1beta and TGFbeta as well as release of MMPs
- This leads to degradation of the extracellular matrix as well as migration of epithelial cells, facilitating fistula formation
What is the evidence for antibiotics in perianal fistula treatment?
-
Randomised evidence to show reduced fistula rates after I+D of perianal abscess (14% versus 31%)
- 7-day course of Cipro and Metronidazole
- There is evidence from small trials in patients with Crohn’s disease that the use of antibiotics alone can lead to fistula closure
- Of note, the original description of the LIFT procedure includes 2 weeks of Ciprofloxacin and Metronidazole post op.
What modifiable factors promote or facilitate perianal fistulisation?
FRIENDS again…
Foreign body (therapeutic Seton!)
Radiation or tissue damage causing chronic inflammatory change
Inflammation around the fistula
Epithelialisation (reflects chronicity)
Neoplasia
Distal obstruction; in this setting the high pressure zone
Sepsis or bacterial load
Classify fistula-in-ano in terms of management categories
Simple (laying open fistula)
- Intersphincteric
- Transphincteric <30% of the sphincter complex involved
Complex (draining Seton for at least 6 weeks…)
- Transphincteric >30%
- Suprasphincteric (cannot have have L.I.F.T)
- Extrasphincteric
- Any fistula with
- Concomittant anorectal disease
- Crohn’s
- TB/HIV
- Radiotherapy
- Cancer
- Multiple tracts
- Recurrent fistula
- Anterior fistula in a woman
- Faecal incontinence
- Concomittant anorectal disease
What factors need to be considered when estimating liklihood of incontinence following fistulotomy?
- Current degree of continence
- Age
- Presence of IBS
- Previous childbirth
- Previous anorectal surgery
- Anoreceptive intercourse
- Previous irradiation
- Underlying neurological disorders.



